Clients

Paratek Pharmaceuticals

Company Snapshot: Paratek Pharmaceuticals

PRTK
Last Change Volume High Low

Company Overview

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The company’s lead product candidate, Omadacycline, is a novel investigational antibiotic with both once-daily intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections (UTI). A modernized tetracycline, omadacycline is specifically designed to overcome tetracycline resistance and exhibits activity across a broad spectrum of bacteria, including Gram-positive, Gram-negative, anaerobes, atypical bacteria, and other drug-resistant strains.

Client News

  1. Mar 1 2021 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  2. Feb 24 2021 Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
  3. Feb 18 2021 Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
  4. Feb 17 2021 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021